BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0
To Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Reports Recent Business Progress and First Quarter 2026 Financial Results
Annual Report to Security Holders
Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Travis Thompson Appointed CFO; Alethia Young Departs Bicycle Therapeutics
Highlights 2025 Accomplishments and Strategic Priorities for 2026
Reports Recent Business Progress and Third Quarter 2025 Financial Results
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence